L’Institut de Cancérologie de l’Ouest located in the Atlantic France region has joined the global health research network TriNetX in order to strengthen collaboration in cancer research and increase ICO’s visibility.
Cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, according to the World Health Organization. By integrating one of the leading French cancer centers to its global network, TriNetX aims to strengthen the research capabilities of L’Institut de Cancérologie de l’Ouest (ICO).
L’Institut de Cancérologie de l’Ouest: 46,000 patients per year
The ICO cancer institute employs 1,340 people and treats more than 46,000 cancer patients per year across two sites in Saint-Herblain and Angers, in the Atlantic France region.
It is the most important cancer center in this region and the third nationally. With 99,000 sessions per year, ICO is the biggest radiotherapy center in France and a pioneer in the field of breast reconstruction.
First French cancer center to join the international network
One of the leading cancer centers in France, ICO is the first to join the network TriNetX. The purpose of this collaborative work is to promote innovative patient care, encourage clinical research, and boost optimisation of therapeutic strategies.
With its self-service platform, TriNetX brings together healthcare organisations and life science companies conducting real-world research to accelerate the development of new therapies.
The global health network will allow ICO to be connected to a large international community specialised in tomorrow’s therapies and healthcare. This joint effort “will increase the visibility of ICO and facilitate collaborative clinical research and real-world evidence studies” said Guillaume Mercusot, its Director of innovation and development.